New IOL ideal for paediatric cataract procedures

Article

A novel, patented multi-component IOL (IVO Lens, InfinitVision Optics) allows for postoperative adjustments for changes in refraction, making it an ideal solution for paediatric cataract surgery, according to a recent report.

A novel, patented multi-component IOL (IVO Lens, InfinitVision Optics) allows for postoperative adjustments for changes in refraction, making it an ideal solution for paediatric cataract surgery, according to a report published in the January 2014 issue of the Journal of Refractive Surgery.

"Paediatric cataract surgery is essentially different from adult cataract surgery," wrote Dr Dimitra M. Portaliou and colleagues from the Institute of Vision and Optics at the University of Crete, Greece. "In paediatric cataract surgery, additional risks are present and postoperative complications may jeopardize and otherwise successful surgical intervention. One of the main considerations is the ongoing postoperative evolution of the power of IOL needed to correct children's eyes. A solution to the problem is provided by the development of the new, innovative, multicomponent InfiniteVision Optics IOL that will allow postoperative adjustments for postoperative changes in refraction," they wrote.

This lens remains adjustable throughout the patient’s lifetime, and allows for the addition and combination of presbyopic and astigmatic correction. It is comprised of two components: a base lens (posterior component) that has a platehaptic configuration, contains only spherical correction, and is implanted in a capsular bag, like a conventional posterior chamber IOL; and a front lens assembly with two haptics extending from the optic. These haptics have been designed to fit into two small bridges projecting off of the anterior surface of the base lens, securing both components together.

The front lens assembly allows for spherical, cylindrical, and multifocal primary corrections immediately and over time. The lens is implanted through a 1.8-mm to 2.8-mm incision, and is easily assembled inside the eye.

A feasibility study trial with the IVO lens included 6 eyes in 6 patients, with a mean age of 63.3 years. At 2 years' post-op, mean uncorrected visual acuity (from 9.11 to 0.68) and corrected distance visual acuity (from 0.28 to 0.83; P

For more information, click here.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.